New study evaluates effectiveness of weight loss surgery in individuals with obesity, diabetes
The paper, now published in the Molecular Metabolism journal, demonstrates how the researchers reached these results: they used an animal model, comparing groups with iRhom2 deletion to controls, and feeding them with normal diet versus a high fat diet.
Surprisingly, they found that during obesity, iRhom2 protein levels increase specifically in brown adipose tissue in obese animals compared to controls. Following up on this, they found that, on a high fat diet, the animals lacking iRhom2 protein were metabolically more healthy than their wild type counterparts.
Marina Badenes, a researcher and the main author of the paper, explains that "the deletion of iRhom2 led to enhanced energy consumption in adipose tissue, which protected animals from fat accumulation and inflammation, fatty liver and insulin resistance when the animals were placed on a diet that predisposed them to obesity". Furthermore, the researchers found that "at the cellular level deletion of iRhom2 leads to an increase in thermogenesis (heat production) in brown adipose tissue. Thermogenesis in brown adipose tissue is an important physiological mechanism to consume excess body energy".
Interestingly no deleterious side effects were found in the animals with iRhom2 deletion, indicating that blocking iRhom2 may potentially be beneficial in the treatment of obesity and associated complications. Researchers intend to continue the project to further understand the mechanisms and cell types involved in the iRhom2 control of obesity. They also want to find out the specific targets involved in the protection against obesity associated with loss of iRhom2. Source:
Instituto Gulbenkian de Ciencia Journal reference:
Badenes, M., et al. (2020) Deletion of iRhom2 protects against diet-induced obesity by increasing thermogenesis. Molecular Metabolism . doi.org/10.1016/j.molmet.2019.10.006 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology